Avantis International Small Cap Value ETF vs GSK plc — how do they compare? Avantis International Small Cap Value ETF trades at $110.21, while GSK plc trades at $50.42 (market cap $102.60B). The key difference: GSK plc pays a 3.57% dividend while Avantis International Small Cap Value ETF pays none, and Avantis International Small Cap Value ETF is trading nearer its 52-week high, GSK plc nearer its low. Which is the better fit depends on your goals.
| AVDV | GSK | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $110.40 | $61.18 |
52-Week Low | $83.89 | $38.22 |
Market Cap | — | $102.60B |
Enterprise Value | — | $123.04B |
Dividend Yield | — | 3.57% |
Signals from Pluang's Aura AI — not financial advice
AVDV trades at $110.51, up 0.96% today, with a bullish technical outlook from moving averages but caution from oscillators like the 6-day RSI at 87.64 indicating overbought conditions. Recent news highlights strong 2026 performance, with international small-cap value strategies gaining attention. The stock shows support near $108-$109 and resistance at $110.
The outlook remains positive due to momentum in international small-cap value, though overbought signals and reliance on commodity sectors pose risks. Investors should weigh the ETF's diversification benefits against potential volatility from global economic shifts.
GSK trades at $50.30, down 3.57% today, with a bearish technical signal from moving averages. The company reported strong Q2 2026 earnings of $1.36 per share, beating estimates of $1.27, and announced a $2.52 billion cost-saving plan through 2029. Revenue growth remains steady at 5% constant currency, supported by vaccines and specialty medicines. Analyst consensus shows 31% buy ratings with 55% hold, indicating cautious optimism.
GSK's solid profitability and strategic cost initiatives support long-term growth, but near-term stock performance faces headwinds from bearish technicals and mixed analyst sentiment. Key risks include pipeline execution and regulatory challenges, while institutional ownership trends and recent FDA approvals provide stability. The current valuation at 16.02 P/E offers reasonable entry for patient investors.
Trailing returns across standard periods
Latest headlines on both assets
AVDV is an actively managed ETF that targets small-cap value companies in developed markets outside the United States. It uses a systematic, rules-based process to identify firms trading at low valuations with high profitability, aiming to capture the 'size' and 'value' premiums while maintaining broad diversification.
Read more on AVDV →In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →